https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Galectin-3: its role in asthma and potential as an anti-inflammatory target https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17053 Wed 11 Apr 2018 15:00:47 AEST ]]> Anti-inflammatory deficiencies in neutrophilic asthma: reduced galectin-3 and IL-1RA/IL-1β https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27569 Wed 11 Apr 2018 11:56:33 AEST ]]> Sputum inflammatory cell-based classification of patients with acute exacerbation of chronic obstructive pulmonary disease https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:15055 Wed 11 Apr 2018 09:51:04 AEST ]]> Severe and uncontrolled asthma in China: a cross-sectional survey from the Australasian Severe Asthma Network https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32190 Wed 09 Mar 2022 16:01:03 AEDT ]]> Clinical Subtypes of Neutrophilic Asthma: A Cluster Analysis From Australasian Severe Asthma Network https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54912 Thu 21 Mar 2024 12:03:37 AEDT ]]> The safety of sputum induction in adults with acute exacerbation of COPD https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18986 20% occurred in only one subject with AECOPD who was in GOLD category III. The decrease in percentage of FEV1 from baseline was greatest in the second stage of induction, and correlated with that of the final stage (r = 0.589; P = 0.01). The fall in FEV1 during induction increased with GOLD category (P < 0.05). Conclusions: SI can be safely and successfully performed in patients with moderate to very severe chronic obstructive pulmonary disease who experience an exacerbation using this modified induction protocol. The early decrease in FEV1 can be used to predict the maximum fall.]]> Sat 24 Mar 2018 07:58:51 AEDT ]]>